Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of $840.00.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Key Points President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports.Lilly's margins could be negatively affected if the company absorbs the higher costs.However, any ...

The company also raised its full-year outlook, and the stock rallied over 15% since it reported the Q2 numbers. In this note, we discuss Eli Lilly’s stock performance, key takeaways from its ...

Over the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%. With ...

Eli Lilly’s stock rises as results beat expectations, Mounjaro sales surge Drugmaker trims full-year outlook as it digests a string of recent acquisitions. Last Updated: Nov. 2, ...

Shares of Eli Lilly & Co. LLY inched 0.09% higher to $865.82 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.27% to ...

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $964.46, a high estimate of $1125.00, and a low estimate of $884.00.